{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"0.683","value":"0.583"},{"groupId":"OG001","lowerLimit":"0.5","upperLimit":"0.633","value":"0.583"},{"groupId":"OG002","lowerLimit":"0.633","upperLimit":"0.717","value":"0.65"},{"groupId":"OG003","lowerLimit":"0.667","upperLimit":"2.33","value":"0.667"},{"groupId":"OG004","lowerLimit":"4.22","upperLimit":"65.9","value":"33.1"},{"groupId":"OG005","lowerLimit":"2.0","upperLimit":"20.3","value":"6.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"description":"time of the observed maximum concentration (Tmax)","dispersionType":"Full Range","groups":[{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG000","title":"Cohort 1: N-803 - IV 1 ug/kg"},{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG001","title":"Cohort 2: N-803 - IV 3 ug/kg"},{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG002","title":"Cohort 3: N-803 - IV 6 ug/kg"},{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG003","title":"Cohort 4: N-803 - IV 10 ug/kg"},{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG004","title":"Cohort 5: N-803 - SQ 10 ug/kg"},{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG005","title":"Cohort 6: N-803 - SQ 15 ug/kg"}],"paramType":"MEDIAN","populationDescription":"Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects","reportingStatus":"POSTED","timeFrame":"PK timepoint up to 72 hours +/- 6 hours","title":"Characterization of the Pharmacokinetic Profile - Time of the Observed Maximum Concentration (Tmax)","type":"SECONDARY","unitOfMeasure":"Hours"}